OR WAIT 15 SECS
Internationalization and regulatory reform are driving growth and investment China.
Organizers of CPhI and P-MEC China, scheduled for June 20–22, 2018 at the Shanghai New International Expo Center, announced on May 18, 2018 expected growth in international attendance at the 2018 event as global companies seek to capitalize on investment opportunities in the region.
CPhI reported in a press statement that according to the 2017 CPhI Global Pharma Index, China remains a region with unmatched growth potential and projects total pharmaceutical sales to be $158 billion in 2018. Recent regulatory reforms by the China Food and Drug Administration, efforts to harmonize China’s regulations with international other global authorities, clinical trial reforms, and government efforts to encourage innovation are factors promoting international attendance, the organizers report.
CPhI reports that China has the most pharma manufacturers in the world, with 6500 companies producing 1500 APIs. Due to rapid growth of generic-drug production in China for domestic and exports consumption, CPhI China introduced an excipients zone named PharmaExcipients. A dedicated Animal Health & Feed zone also was launched.
An inaugural one-day International Business Programme will feature two tracks. One track will cover topics for the international pharma community interested in conducting business in the Chinese market; the second track will address the needs of Chinese companies who are looking to grow operations internationally.
Cited as Asia’s largest pharmaceutical event, CPhI is co-located with ICSE, InnoPack, BioPh, Labworld, NEX, EP & Clean Tech, FDF, P-Logi, and PharmaExcipients. Country pavilions from Russia, Brazil, and Poland have been added for 2018.
The organizers expect 45,000 attendees and 3000 exhibitors from more than 120 countries, a year-on-year increase of 8% and 20%, respectively. Pre-registration figures indicate that US attendance at the event has risen by 53%, CPhI reports.
“The Chinese pharma economy has expanded vastly in recent years, with regulatory reforms- particularly China joining the ICH towards the end of 2017-spurring international interest in the region,” commented Marie Lagrenee, brand manager of CPhI China, UBM in a press statement. “In addition, many overseas trained scientists are returning to fuel the growth of a rapidly expanding R&D sector, attracting significant attention from international pharma companies. At such an important time, it is vital that events such as CPhI China provide a platform to facilitate new deals, exchange ideas, and drive growth in this thriving market,” added Lagrenee.
CPhI China is organized by UBM and UBM SINEXPO. CPhI and Pharmaceutical Technology are UBM brands.